Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic SMA: long-term follow-up study

被引：0
|
作者：
Darras, B. [1 ]
Farrar, M. [2 ,3 ]
Mercuri, E. [4 ,5 ]
Strauss, K. [6 ,7 ,8 ]
Day, J. [9 ]
Chien, Y. [10 ]
Masson, R. [11 ]
Bernardo, R. [12 ]
Alecu, I. [13 ]
Dodd, N. [14 ]
Mehl, L. [15 ]
Connolly, A. [16 ,17 ]
机构：
[1] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA
[2] Sydney Childrens Hosp Network, Sydney, NSW, Australia
[3] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia
[4] Catholic Univ, Dept Paediat Neurol, Rome, Italy
[5] Catholic Univ, Nemo Clin Ctr, Rome, Italy
[6] Clin Special Children, Strasburg, PA USA
[7] Penn Med Lancaster Gen Hosp, Lancaster, PA USA
[8] Univ Massachusetts, Sch Med, Worcester, MA USA
[9] Stanford Univ, Med Ctr, Stanford, CA USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[12] Novartis Global Drug Dev Neurosci & Gene Therap, E Hanover, NJ USA
[13] Novartis Pharmaceut, Basel, Switzerland
[14] Novartis Gene Therapies Inc, Bannockburn, IL USA
[15] Novartis, BioMed Res, Cambridge, MA USA
[16] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA
[17] Ohio State Univ, Coll Med, Columbus, OH USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
179P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic spinal muscular atrophy (SMA): long-term follow-up study
    Darras, B.
    Mercuri, E.
    Strauss, K.
    Day, J.
    Chien, Y.
    Masson, R.
    Wigderson, M.
    Alecu, I.
    Ballarini, N.
    Mehl, L.
    Marra, J.
    Connolly, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S87 - S87
  • [2] Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study
    Darras, Basil
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Chien, Yin-Hsiu
    Masson, Ricardo
    Wigderson, Melissa
    Alecu, Iulian
    Ballarini, Nicolas
    Mehl, Lesa
    Marra, Jonathan
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [3] Long-term follow-up (LTFU) of onasemnogene abeparvovec gene therapy in spinal muscular atrophy (SMA)
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Day, J.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S132 - S133
  • [4] Long-term Follow-up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Day, J.
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    ANNALS OF NEUROLOGY, 2021, 90 : S151 - S152
  • [5] Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Mendell, Jerry
    Finkel, Richard
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Kleyn, Aaron
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    Meriggioli, Matthew
    NEUROLOGY, 2021, 96 (15)
  • [6] Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1
    Mendell, J.
    Wigderson, M.
    Alecu, I.
    Yang, L.
    Mehl, L.
    Connolly, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S91 - S91
  • [7] Long-term follow-up of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1 (SMA1)
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Joshi, S.
    Sproule, D.
    Meriggioli, M.
    Feltner, D.
    Al-Zaidy, S.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S123
  • [8] Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1
    Mendell, Jerry
    Wigderson, Melissa
    Alecu, Iulian
    Yang, Lina
    Mehl, Lesa
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [9] LONG-TERM FOLLOW-UP OF THE PHASE 1 START TRIAL OF ONASEMNOGENE ABEPARVOVEC GENE THERAPY IN SPINAL MUSCULAR ATROPHY TYPE 1
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Kausar, I.
    Reyna, S. P.
    Meriggioli, M.
    Kleyn, A.
    Al-Zaidy, S.
    THORAX, 2021, 76 : A10 - A10
  • [10] Gene Therapy in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up (LTFU) From the Onasemnogene Abeparvovec Phase 1 Clinical Trial
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Baldinetti, F.
    Ogrinc, F. G.
    Ouyang, H.
    Kernbauer, E.
    Joshi, S.
    Sproule, D. M.
    Meriggioli, M.
    Feltner, D. E.
    Al-Zaidy, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 165 - 165
12345